Novel non-β-lactam inhibitor of β-lactamase TEM-171 based on acylated phenoxyaniline

Biochimie

Volumn 132, Issue , 2017, Pages 45-53

  Grigorenko, V G ^a   Andreeva, I P ^a   Rubtsova, M Yu ^a   Deygen, I M ^a   Antipin, R L ^a   Majouga, A G ^a   Egorov, A M ^a   Beshnova, D A ^b   Kallio, J ^b   Hackenberg, C ^b   Lamzin, V S ^b  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Antibiotic resistance; Lead discovery; Non lactam inhibitor; Recombinant lactamase TEM

Indexed keywords

4 OXO 4 [[4 (2,4 DICHLOROPHENOXY)PHENYL]AMINO]BUTANOIC ACID; ANILINE DERIVATIVE; BETA LACTAMASE INHIBITOR; BETA LACTAMASE TEM 171; HYDROLASE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DNA SEQUENCE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME KINETICS; HYDROGEN BOND; INFRARED SPECTROSCOPY; INHIBITION CONSTANT; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; PROTEIN EXPRESSION; ACYLATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; FLUORESCENCE; KINETICS; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCEDURES;

ACYLATION; ANILINE COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; DRUG DISCOVERY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENCE; KINETICS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84994378118     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2016.10.011     Document Type: Article

References (40)

1. [1] Fisher, J.F., Meroueh, S.O., Mobashery, S., Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:2 (2005), 395–424.
2. [2] Antimicrobial Resistance Global Report on Surveillance, 2014, World Health Organization http://www.who.int/drugresistance/en/.
3. [3] Blumberg, P.M., Strominger, J.L., Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol. Rev. 38:3 (1974), 291–335.
4. [4] Smith, J.T., Hamilton-Miller, J.M., Knox, R., Bacterial resistance to penicillins and cephalosporins. J. Pharmacol. 21:6 (1969), 337–358.
5. [5] Carlet, J., Collignon, P., Goldmann, D., Goossens, H., Gyssens, I.C., Harbarth, S., Jarlier, V., Levy, S.B., N'Doye, B., Pittet, D., Richtmann, R., Seto, W.H., Van der Meer, J.W., Voss, A., Society's failure to protect a precious resource: antibiotics. Lancet 378 (2011), 369–371.
6. [6] Baquero, F., Tedim, A.P., Coque, T.M., Antibiotic resistance shaping multi-level population biology of bacteria. Front. Microbiol. 4:15 (2013), 1–15.
7. [7] Tang, S., Apisarnthanarak, A., Hsu, L.Y., Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community-and healthcare-associated multidrug-resistant bacteria. Adv. Drug Deliv. Rev. 78 (2014), 3–13 doi: 101016/jaddr201408003.
8. [8] Ambler, R.P., The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 289 (1980), 321–331.
9. [9] Perez, F., Endimiani, A., Hujer, K.M., Bonomo, R.A., The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7 (2000), 459–469.
10. [10] Pitout, J.D., Laupland, K.B., Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect. Dis. 8 (2008), 159–166, 10.1016/S1473-3099(08)70041-0.
11. [11] Bush, K., Proliferation and significance of clinically relevant β-lactamases. Ann. N.Y. Acad. Sci. 1277 (2013), 84–90.
12. [12] Livermore, D.M., Defining an extended-spectrum beta-lactamase. Clin. Microbiol. Infect. 14:Suppl.1 (2008), 3–10.
13. [13] Roca, I., Akova, M., Baquero, F., Carlet, J., Cavaleri, M., Coenen, S., Cohen, J., Findlay, D., Gyssens, I., Heure, O.E., Kahlmeter, G., Kruse, H., Laxminarayan, R., Liébana, E., López-Cerero, L., MacGowan, A., Martins, M., Rodríguez-Baño, J., Rolain, J.M., Segovia, C., Sigauque, B., Taconelli, E., Wellington, E., Vila, J., The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 6 (2015), 22–29, 10.1016/j.nmni.2015.02.007.
14. [14] Pimenta, A.C., Fernandes, R., Moreira, I.S., Evolution of drug resistance: insight on TEM β-lactamases structure and activity and β-lactam antibiotics. Mini Rev. Med. Chem. 14 (2014), 111–122.
15. [15] Watkins, R.R., Papp-Wallace, K.M., Drawz, S.M., Bonomo, R.A., Novel β-lactamase inhibitors: a therapeutichopeagainst the scourge of multidrugresistance. Front. Microbiol. 4 (2013), 1–8.
16. [16] Drawz, S.M., Bonomo, R.A., Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23 (2010), 160–201.
17. [17] Ehmann, D.E., Jahic, H., Ross, P.L., Gu, R.F., Hu, J., Kern, G., Walkup, G.K., Fisher, S.L., Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor. PNAS 109 (2012), 11663–11668.
18. [18] Horn, J.R., Shoichet, B.K., Allosteric inhibition through core disruption. J. Mol. Biol. 336 (2004), 1283–1291.
19. [19] Yu, C., Shoichet, B.K., Molecular docking and ligand specificity in fragment-based on inhibitor discovery. Nat. Chem. Biol. 5:5 (2009), 358–364.
20. [20] Grigorenko, V.G., Andreeva, I.P., Rubtsova, M.Yu., Burmakin, V.V., Uporov, I.V., Egorov, A.M., Study of catalytic properties of recombinant β-lactamases TEM-1 and TEM-171 of the molecular class A. Mosc. Univ. Chem. Bull. 70:6 (2015), 238–243, 10.3103/S0027131415060036.
21. [21] Laemmli, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:5259 (1970), 680–685.
22. [22] Grigorenko, V.G., Rubtsova, M.Y., Egorov, A.M., Carolan, C.G., Lamzin, V.S., Kallio, J., Combating bacterial antibiotic resistance: novel lactamase inhibitors. FEBS J., 280(Suppl. 1), 2013, 373 SW04.S16-294.
23. [23] Bebrone, C., Moali, C., Mahy, F., Rival, S., Docquier, J.D., Rossolini, G.M., Fastrez, J., Pratt, R.F., Frère, J.M., Galleni, M., CENTA as a chromogenic substrate for studying β-lactamases. Antimicrob. Agents Chemother. 45:6 (2001), 1868–1871.
24. [24] Savitzky, A., Golay, M.J.E., Smoothing and differentiation of data by simplified least squares procedures. Anal. Chem. 36:8 (1964), 1627–1639.
25. [25] Fonze, E., Charlier, P., To'th, Y., Vermeire, M., Raquet, X., Dubus, A., Frere, J.M., TEM-1 Beta-lactamase structure solved by molecular replacement and refined structure of the mutant. ActaCrystallogr D51 (1995), 682–694.
26. [26] O'Boyle, N.M., Banck, M., James, C.A., Morley, C., Vandermeersch, T., Hutchison, G.R., Open Babel: an open chemical toolbox. J. Cheminf, 3, 2011, 33, 10.1186/1758-2946-3-33.
27. [27] Trott, O., Olson, A.J., AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2010), 455–461.
28. [28] Sanner, M.F., Python: a programming language for software integration and development. J. Mol. Graph. Mod. 17 (1999), 57–61.
29. [29] Morandi, F., Caselli, E., Morandi, S., Focia, P.J., Blazquez, J., Shoichet, B.K., Prati, F., Nanomolar inhibitors of AmpC β-lactamase. J. Am. Chem. Soc. 125 (2003), 685–695.
30. [30] Majumdar, S., Pratt, R.F., Inhibition of class A and C β-lactamases by diaroyl phosphates. Biochemistry 48 (2009), 8285–8292.
31. [31] Phichith, D., Bun, S., Padiolleau-Lefevre, S., Guellier, A., Banh, S., Galleni, M., Frere, J.M., Thomas, D., Friboulet, A., Avalle, B., Novel peptide inhibiting both TEM-1 b-lactamase and penicillin-binding proteins. FEBS J. 277 (2010), 4965–4972.
32. [32] Goyne, K.W., Chorover, J., Kubicki, J.D., Zimmerman, A.R., Brantley, S.L., Sorption of the antibiotic ofloxacin to mesoporous and nonporous alumina and silica. J. Colloid Interface Sci. 283 (2005), 160–170.
33. [33] Pandey, S., Pandey, P., Tiwari, G., Tiwari, R., Rai, A.K., FTIR spectroscopy: a tool for quantitative analysis of ciprofloxacin in tablets. Indian J. Pharm. Sci. 71 (2012), 86–90, 10.4103/0250474X.102551.
34. [34] Sahoo, S., Chakraborti, C.K., Mishra, S.C., Naik, S., Nanda, U.N., FTIR and raman spectroscopy as a tool for analyzing sustained release hydrogel of ciprofloxacin/carbopol polymer. Int. J. Pharm. Sci. Res. 2 (2011), 268–277.
35. [35] Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7:3 (1999), 297–307.
36. [36] Malevsky, A.A., Sukhorukov, B.I., IR study of base stacking interaction. Nucleic Acids Res. 8:13 (1980), 3029–3042.
37. [37] Saito, S.T., Silva, G., Pungartnik, C., Brendel, M., Study of DNA-emodin interaction by FTIR and UV-vis spectroscopy. J. Photochem. Photobiol. B Biol. 111 (2012), 59–63.
38. [38] Lakowicz, J.R., Fluorescence spectroscopic investigations of the dynamic properties of proteins, membranes and nucleic acids. J. Biochem. Biophys. Methods 2:1 (1980), 91–119.
39. [39] Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 13 (2004), 1605–1612.
40. [40] Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J.T., Cho, J.M., Yun, G., Lee, J., Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J. Pharm. Sci. 9 (2014), 304–316.